Long-term Treatment With Evolocumab in Patients With Homozygous Familial Hypercholesterolaemia (HoFH): Interim Results from the Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG) Study
Presentation prepared and held by Prof. Frederick Raal (University of Witwatersrand, Johannesburg, South Africa) in Clinical Breakthroughs session: Modifying LDL cholesterol to prevent CV events, Tuesday, May 26, 2015 during ISA2015 (Amsterdam, The Netherlands).
To view slides, click on images
ISA_LS_2015p_TAUSSIG_long_term_Raal.pdf (0,4MB)
To view slides, click on images
ISA_LS_2015p_TAUSSIG_long_term_Raal.pdf (0,4MB)
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
Share this page with your colleagues and friends: